Table 2 The incidence of expression of CCL2, CCL5, TNFα and IL-1β in tumor cells and in adjacent normal breast epithelial cells in DCIS and IDC patients
Expression of chemokines/cytokines in | Number of patients (%) | |||
|---|---|---|---|---|
With CCL2 expression | With CCL5 expression | With TNFα expression | With IL-1β expression | |
DCIS | ||||
Breast malignant cells | 11/27 (40.7%) | 16/27 (59.2%) | 13/27 (48.1%) | 15/27 (55.5%) |
Adjacent normal breast epithelial duct cells | 5/27 (18.5%) | 7/27 (25.9%) | 3/27 (11.1%) | 6/27 (22.2%) |
p value | 0.03 | 0.01 | 0.002 | 0.003 |
IDC-no-relapse | ||||
Breast malignant cells | 10/19 (52.6%) | 15/19 (78.9%) | 14/19 (73.7%) | 13/19 (68.4%) |
Adjacent normal breast epithelial duct cells | 1/19 (5.3%) | 1/19 (5.3%) | 0/19 (0.0%) | 1/19 (5.3%) |
p value | 0.003 | 0.0002 | 0.0001 | 0.0005 |
IDC-with-relapse | ||||
Breast malignant cells | 15/29 (51.7%) | 17/29 (58.6%) | 24/29 (82.7%) | 25/29 (86.2%) |
Adjacent normal breast epithelial duct cells | 3/29 (10.3%) | 2/29 (6.9%) | 6/29 (20.7%) | 8/29 (27.6%) |
p value | 0.001 | 0.0001 | <0.0001 | <0.0001 |